Medtronic

Medtronic runs one of the most active medical-device venture programs in the world, and its Israeli office in Herzliya is a significant node in that activity. The company backs the MindUP incubator and engages directly with Israeli founders working on surgical hardware, robotics, and digital health platforms that complement its global product lines. For founders, this is a strategic relationship with a clear acquirer at the end of the path, not a generic financial round.

The thesis is medical devices and digital health, with a working interest in surgical robotics, neurotechnology, and the growing intersection of devices and software. AI focus is real and reflects the broader shift in the device industry toward platforms that combine hardware, sensing, and machine learning. The strategic logic of a Medtronic check is usually clear: a technology that fits an existing business unit, a capability that extends one, or a category where the company wants early visibility before deciding whether to build, partner, or acquire.

Checks sit in the five to twenty-five million dollar range, deployed at Series A, Series B, and growth, which positions Medtronic as a later-stage participant after the fundamental technical and clinical risk has been retired. Geography for the Herzliya program is anchored in Israel, but the eventual commercial path runs through Medtronic’s global distribution. Founders should expect the discussion to assume that path from early on.

As a corporate venture program inside a global device manufacturer, the team brings deep clinical and regulatory expertise, with all the institutional weight that implies. Decisions involve internal stakeholders beyond the venture team itself, and founders should expect process timelines that reflect that reality.

The approach is strategic and hands-on within its scope. Medtronic can offer access to clinical advisors, manufacturing perspective, regulatory experience, and a credible read on what the broader market will and will not adopt. It can also offer the structural risks that come with corporate VC: a strategic stake that shapes future financings, ROFR-like dynamics in the term sheet that need careful negotiation, and an asymmetric relationship between a public-company investor and a private-company management team. Founders engaging with the program should be specific about which Medtronic business unit the company actually maps to, should negotiate explicitly on information rights and exit dynamics, and should understand that the value of the relationship is heavily concentrated in the operational support and commercial path rather than in the dollars themselves. For surgical and neurotech founders building toward a credible acquirer, the fit can be exact.